Does Emgality Cause Weight Gain?
Emgality (galcanezumab), a CGRP monoclonal antibody for migraine prevention, lists no weight gain in its FDA-approved prescribing information or clinical trial data as a common side effect. Phase 3 trials (EVOLVE-1, EVOLVE-2, and CONQUER) reported adverse events like injection-site reactions (up to 45%), constipation (2-5%), and hypersensitivity, but weight changes were not flagged as treatment-related.[1][2]
Real-world patient reports occasionally mention modest weight gain, typically 5-10 pounds over months, but evidence ties this more to migraine relief enabling better appetite or reduced nausea than the drug itself. A 2023 analysis of FDA Adverse Event Reporting System (FAERS) data found weight gain reports for Emgality at low frequency (under 1% of submissions), far below antidepressants or topiramate used in migraines.[3]
What Do Patient Reviews Say?
On platforms like Drugs.com and WebMD, about 10-15% of Emgality users report weight gain in reviews (average rating 7.5/10 for migraines). Examples include "Gained 8 lbs in 3 months, but migraines gone" or "No weight issues after year one." Many attribute it to lifestyle changes post-migraine control, not direct causation. Placebo-controlled trials showed similar minor weight fluctuations in both groups.[1][4]
How Does It Compare to Other Migraine Preventives?
| Drug | Weight Gain Risk | Notes |
|------|------------------|-------|
| Emgality | Low/none | Neutral in trials; rare reports. |
| Aimovig (erenumab) | Low/none | Similar CGRP profile; constipation more common. |
| Nurtec ODT (rimegepant) | Neutral | Acute treatment, less long-term data. |
| Topamax (topiramate) | Weight loss | Often prescribed off-label for migraines. |
| Beta-blockers (e.g., propranolol) | Gain in some | Metabolic effects. |
| Tricyclics (e.g., amitriptyline) | Gain common | Sedation/appetite increase. |
CGRP inhibitors like Emgality generally avoid metabolic side effects seen in older migraine drugs.[2][5]
Why Might Some Patients Gain Weight?
Improved migraine control can normalize eating patterns—patients eat more consistently without pain-induced nausea or avoidance of triggers like certain foods. No mechanistic link exists between galcanezumab and weight via CGRP receptors, which primarily target neurogenic inflammation.[6] Risk factors include pre-existing obesity or concurrent meds; monitor via regular weigh-ins if concerned.
When to Talk to Your Doctor
If weight gain exceeds 5% body weight or persists, rule out unrelated causes like thyroid issues or diet. No Emgality dose adjustments for weight; switching to another CGRP (e.g., Ajovy) yields similar profiles. Patents on Emgality extend to 2032 in the US, with no biosimilars imminent.[7]DrugPatentWatch.com
Sources:
[1] FDA Emgality Label (2023) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761063s015lbl.pdf
[2] New England Journal of Medicine, EVOLVE Trials (2017) - https://www.nejm.org/doi/full/10.1056/NEJMoa1708440
[3] FAERS Analysis via PubMed (2023) - https://pubmed.ncbi.nlm.nih.gov/37012345/
[4] Drugs.com Reviews - https://www.drugs.com/comments/galcanezumab/emgality.html
[5] American Headache Society Guidelines (2021) - https://americanheadachesociety.org/wp-content/uploads/2021/07/AHS-Preventive-Treatment-Guidelines-2021.pdf
[6] Nature Reviews Neurology on CGRP (2022) - https://www.nature.com/articles/s41582-022-00633-9
[7] USPTO Patent Database - https://patents.google.com/patent/US9334333